Clinical Significance of MRI ‐Suspicious Lesion Visibility on 29‐ MHz Micro‐Ultrasound During MRI –Ultrasound Fusion Targeted Prostate Biopsy
International Journal of Urology · 2026-11 · 33 (11)
DOI: 10.1111/iju.70720 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Urology, online erschienen am 13.11.2026. Verfasst von Akio Takayanagi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, JCHO Hokkaido Hospital, Sapporo, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Image-Guided Biopsy, Prostate, Magnetic Resonance Imaging. Die Arbeit nennt 17 Literaturangaben.
Abstract (Originalsprache)
Objectives
To evaluate whether the visibility of MRI‐suspicious lesions on 29‐MHz micro‐ultrasound is associated with targeted biopsy outcomes during MRI–ultrasound fusion transperineal prostate biopsy.
Methods
This retrospective observational study included 238 patients who underwent MRI–ultrasound fusion transperineal prostate biopsy between November 2023 and October 2025. Systematic biopsy was performed using a 10‐core transperineal template, and targeted biopsy was performed with three cores per MRI‐suspicious lesion. MRI‐suspicious lesions were evaluated during the biopsy procedure using 29‐MHz micro‐ultrasound and classified as visible or invisible. Logistic regression analysis was performed to evaluate predictors of Grade Group (GG) ≥ 2 and GG ≥ 3 cancer detection in targeted biopsy.
Results
MRI‐suspicious lesions were visible on 29‐MHz micro‐ultrasound in 171 patients (71.8%) and invisible in 67 (28.2%). In targeted biopsy, visible lesions showed higher detection rates of prostate cancer, GG ≥ 2 cancer, GG ≥ 3 cancer, and GG ≥ 4 cancer than invisible lesions: 66.7% versus 28.4%, 55.0% versus 16.4%, 35.1% versus 7.5%, and 15.8% versus 1.5%, respectively. Among cancers detected by targeted biopsy, micro‐ultrasound visibility was observed in 85.7% of all prostate cancers, 89.5% of GG ≥ 2, 92.3% of GG ≥ 3, and 96.4% of GG ≥ 4 cancer. In multivariable analysis, micro‐ultrasound visibility remained independently associated with GG ≥ 2 cancer (odds ratio [OR], 3.80; p < 0.001) and GG ≥ 3 cancer (OR, 3.94; p = 0.009).
Conclusions
Visibility of MRI‐suspicious lesions on 29‐MHz micro‐ultrasound was independently associated with clinically significant prostate cancer detection. Micro‐ultrasound visibility may provide useful real‐time adjunctive information during MRI–ultrasound fusion biopsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, JCHO Hokkaido Hospital, Sapporo, Japan.
- Department of Urology, Hakodate Goryoukaku Hospital, Hakodate, Japan.
- Department of Urology, NTT East Sapporo Hospital, Sapporo, Japan.
- Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Department of Urology, Takikawa Municipal Hospital, Takikawa, Japan.
ORCID-Profile: Akio Takayanagi, Souichiro Murayama, Yoko Saito
Zitieren
APA
Takayanagi, A., Murayama, S., Nishio, Y., Saito, Y., Kozen, N., Ueki, Y., Toyota, T., & Okabe, K. (2026). Clinical Significance of MRI ‐Suspicious Lesion Visibility on 29‐ MHz Micro‐Ultrasound During MRI –Ultrasound Fusion Targeted Prostate Biopsy. International Journal of Urology, 33(11). https://doi.org/10.1111/iju.70720
Vancouver
Takayanagi A, Murayama S, Nishio Y, Saito Y, Kozen N, Ueki Y, et al. Clinical Significance of MRI ‐Suspicious Lesion Visibility on 29‐ MHz Micro‐Ultrasound During MRI –Ultrasound Fusion Targeted Prostate Biopsy. International Journal of Urology. 2026;33(11). doi:10.1111/iju.70720
BibTeX
@article{Takayanagi2026,
author = {Takayanagi, Akio and Murayama, Souichiro and Nishio, Yuuki and Saito, Yoko and Kozen, Nodoka and Ueki, Yohei and Toyota, Tomohiro and Okabe, Ko},
title = {Clinical Significance of MRI ‐Suspicious Lesion Visibility on 29‐ MHz Micro‐Ultrasound During MRI –Ultrasound Fusion Targeted Prostate Biopsy},
journal = {International Journal of Urology},
year = {2026},
volume = {33},
number = {11},
doi = {10.1111/iju.70720}
}
EUVIMED